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Chronic Disease Medication Use in
Managed Care and Indemnity
Insurance Plans
Randall S. Stafford, Stephen M. Davidson, Harriet Davidson,
Heidi Miracle-McMahill, Sybil L. Crawford, and David Blumenthal
Objective. To evaluate the impact of managed care on the use of chronic disease
medications.
Data Source. Claims data from 1997 from two indemnity and three independent
practice association (IPA) model managed care insurance plans.
Research Design. Cross-sectional analysis of claims data.
Data Collection. Adult patients with diabetes mellitus (DM, n5 26,444), congestive
heart failure (CHF, n57,978), and asthma (n59,850) were identified by ICD-9 codes.
Chronic disease medication use was defined through pharmacy claims for patients
receiving one or more prescriptions for drugs used in treating these conditions. Using
multiple logistic regression we adjusted for patient case mix and the number of primary
care visits.
Principal Findings. With few exceptions, managed care patients were more likely to
use chronic disease medications than indemnity patients. In DM, managed care patients
were more likely to use sulfonylureas (43 percent versus 39 percent for indemnity),
metformin (26 percent versus 18 percent), and troglitazone (8.8 percent versus 6.4
percent), but not insulin. For CHF patients, managed care patients were more likely to
use loop diuretics (45 percent versus 41 percent), ACE inhibitors or angiotensin receptor
blockers (50 percent versus 41 percent), and beta-blockers (23 percent versus 16
percent), but we found no differences in digoxin use. In asthma, managed care patients
were more likely to use inhaled corticosteroids (34 percent versus 30 percent), systemic
corticosteroids (18 percent versus 16 percent), short-acting beta-agonists (42 percent
versus 33 percent), long-acting beta-agonists (9.9 percent versus 8.6 percent), and
leukotriene modifiers (5.4 percent versus 4.1 percent), but not cromolyn or
methylxanthines. Statistically significant differences remained after multivariate analysis
that controlled for age, gender, and severity.
Conclusions. Chronic disease patients in these managed care plans are more likely to
receive both inexpensive and expensive medications. Exceptions included older
medications partly supplanted by newer therapies. Differences may be explained by the
fact that patients in indemnity plans face higher out-of-pocket costs and managed care
plans promote more aggressive medication use. The relatively low likelihood of
condition-specific medications in both plan types is a matter of concern, however.
Key Words. Managed care, physician practice patterns, medication prescribing,
chronic disease
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There is substantial concern that incentives embedded in managed care (MC)
will result in compromised quality of care (Druss et al. 2000). By shifting
financial risk to the providers of care, the fear is that services may be withheld
or delayed for economic reasons. The use of medications in the treatment of
chronic medical conditions may be particularly susceptible to these forces
because of the long-term need for costly therapy. If financial constraints cause
key medications to be underused, then MC could result in reduced quality of
care, especially for patients with chronic conditions. The growing elderly
population and the promotion of MC for the Medicare population makes this
a critical issue.
Measurement of quality of care across the national spectrum of MC
plans through the Health Plan Employer Data and Information Set (HEDIS,
National Committee for Quality Assurance 1999) and other measures suggest
that many indicators fall short of expectation and vary substantially among
plans. Although those results show apparent deficits for MC patients
compared to a norm, it is not clear whether they are disadvantaged compared
to non-MC patients. Past studies have reported a range of findings, with some
noting superior quality of care in MC and others noting inferior quality (Miller
and Luft 1994, 1997, 2002; Hellinger 1998). No consistent differences have
been observed, although a predominance of findings is consistent with equal
or somewhat better quality in MC. Likewise, there are no consistent
differences in patterns of medication use, although several studies suggest
greater medication use among chronic disease patients in MC. The reason for
the latter finding may reflect higher levels of benefits available to MC
members or lower out-of-pocket expenses associated with seeking this service
(Sullivan 1999; Miller and Luft 2002).
This study was supported by research grant no. 032509 from the Robert Wood Johnson
Foundation to Beth Israel Deaconess Medical Center, Harriet Davidson, Ph.D., Principal
Investigator
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To answer continuing questions about patterns of medication use in MC,
we have acquired and analyzed claims data from multiple health plans in a
single market for patients with a range of chronic conditions. Consistent with
widely held perceptions of MC (Hilzenrath 1997), we specifically test whether
medication therapy for diabetes mellitus (DM), congestive heart failure (CHF),
and asthma were less likely for MC patients and whether their adoption of
newer therapies by MC patients was less rapid.
METHODS
Data Source
This study reports data from a midsize northeastern city with substantial MC
penetration. As in most areas, employers arranged for much of the
population’s health insurance coverage and paid a portion of the employees’
premiums. The MC organizations in this study were of the Independent
Practice Association (IPA) model in which physicians belong to organizations
(IPAs) that contract with the MC plans on their behalf. Both the MC plans and
the IPAs were at financial risk, in that expenditures in excess of premium
revenues would result in fiscal deficits. Similar to indemnity arrangements,
however, payments were made by the MC plans to physicians and other
providers based on claims for services rendered. Many of the same physicians
cared for both MC and indemnity patients. In addition to two large private
MC plans, residents were covered by a large indemnity plan and by MC and
non-MC Medicare plans. Although the state’s Medicaid program was not
included in the study, the data are otherwise representative of the region’s
insured population.
The study uses records of paid medical and pharmacy claims from all
five plans (three MC and two indemnity) for 1997. Of the three managed care
plans, one was a risk-based Medicare plan, and the other two were employer-
based plans. Of the indemnity plans, one was a Medicare plan, including
Medigap supplement, while the other was an employer-based plan. For all
insurers, including the MC plans, individual providers and pharmacies were
paid on the basis of claims submitted. Three separate pharmaceutical benefits
managers processed pharmacy claims. By aggregating claims records from the
five plans, we constructed a complete record of services received by members
in the sample. Because the large number of within-type variations in coverage,
including those for pharmacy benefits, made it infeasible to examine the
effects of individual insurance policy characteristics (e.g., by the amount of a
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policy’s deductible), data were aggregated by the two plan types (i.e., MC and
indemnity insurance). All patients covered by managed care plans faced no
deductible before being eligible for services under their plans and usually paid
only modest copayments out-of-pocket for each service received and
prescription filled. In contrast, patients covered by indemnity plans faced
out-of-pocket patient payments of several hundred dollars for deductibles as
well as coinsurance for each service used, including prescriptions.1
Our principal outcome was the pattern of disease-specific medications
received by patients with diagnoses of DM, CHF, and asthma. Both
physicians’ prescribing and patients’ prescription-filling behavior influence
these patterns. Diabetes mellitus, CHF, and asthma were chosen because these
chronic conditions are highly prevalent, contribute substantially to health care
costs, and disease management (especially medication use) plays a key role in
determining health outcomes. The role of medications differs for each
condition. Diabetes mellitus management focuses on the prevention of acute
decompensation and of long-term complications through a variety of
potentially substitutable or combinable medications that lower blood sugar.
Congestive heart failure management is focused on symptom relief and
prevention of decompensation through medications that maintain adequate
function of a failing heart through a variety of mechanisms. Asthma symptom
alleviation and the prevention of flare-ups are achieved through medications
that either reduce airway inflammation or directly reverse airway constriction.
We identified adult (18 years or older) members of plans in our sample who
had a diagnosis of asthma, DM, or CHF based on International Classification of
Disease Codes-Ninth Revision (ICD-9) diagnoses on medical claims.2 Both
inpatient and outpatient claims were included in this process and members
could be included in more than one diagnosis category.
To simplify the analysis, we included only members who were covered
for the full year by either an MC plan or an indemnity plan. This yielded
26,444 members with DM, 7,978 with CHF, and 9,850 with asthma.
Indemnity plans had 10,440 members with DM, 5,103 with CHF, and 1,981
with asthma. Managed care plans had 16,004 members with DM, 2,875 with
CHF, and 7,869 with asthma. Distribution of members by gender was similar
for indemnity (42 percent male) and managed care plans (46 percent male).
Indemnity members were more likely to be older than 65 years old (73
percent) compared to managed care members (26 percent, p o 0.001).
Correspondingly, disease severity was greater among indemnity members
than those in managed care. The mean health status score using the Diagnostic
Cost Group software (DxCG, Inc. 1999) was 5.47 (standard deviation 9.44) for
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indemnity members and 2.66 (standard deviation 5.73) for those in managed
care.
For each chronic disease, we used drug names and Generic Product
Identifier (GPI) drug codes (MediSpan, Indianapolis, IN) on outpatient
pharmacy claims to identify disease-specific classes of medications that figure
prominently in chronic disease management. For DM, we examined insulin,
sulfonylureas (first and second generations), metformin, and troglitazone. For
CHF, we examined loop diuretics, beta-blockers, angiotensin-converting
enzyme (ACE) inhibitors/angiotensin-2 receptor blockers (ARBs), and
digoxin. For asthma, we examined use of inhaled and systemic corticosteroids,
short- and long-acting beta-agonists, cromolyn sodium (and related com-
pounds), methylxanthines, and leukotriene modifiers. We calculated the
proportion of patients with each disease obtaining one or more prescriptions
for these medication classes during 1997.
Statistical Analyses
We compared the use of these medications by chronically ill persons with MC
and indemnity coverage. Unadjusted proportions of members who received
specific classes of medication were calculated separately for those in
indemnity and MC plans. Unadjusted odds ratios and 95 percent confidence
intervals were calculated comparing the proportion of indemnity patients to
MC patients receiving each drug class at least once during the year. Odds
ratios above 1.00 reflect greater likelihood of use among MC compared to
indemnity patients.
Because patient factors affect whether they receive specific medications,
we used logistic regression modeling to adjust the comparisons for several
potential confounders: age, gender, health status or risk, number of primary
care visits, and specific comorbidities. Risk-adjustment information was
derived from the Diagnostic Cost Groups methodology (DxCG, Inc. 1999).
Logistic regression models were developed for each medication class
controlling for age, gender, number of primary care visits, the presence of
specific comorbidities defined by DxCG condition categories, and the health
risk score derived from the DxCG methodology (representing future
predicted resource use). In each of these three disease-specific models, age
was defined in the categories of o30, 30–45, 46–60, 61–74, and 751years.
The number of primary care visits were grouped as 0, 1, 2, 3–4, 5–6, 7–8, 9–10,
11–20, and 211 visits in 1997. The health risk score was that derived using
ICD-9 codes from all inpatient and direct contact outpatient encounters to
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predict health care resource use with the DxCG concurrent risk model. These
risk scores were categorized into five strata for the regression analysis. This
DxCG model also identified each member’s status on a range of hierarchical
condition categories (HCCs).3
Because of the disproportionate number of elderly with indemnity
insurance, we also analyzed the patterns of medication use rates separately for
patients younger than age 65 and those aged 65 and older as proxies for
commercial plans and Medicare, respectively.
RESULTS
With few exceptions, MC patients were more likely to use chronic disease
medications than indemnity patients with the selected chronic diseases
(Table 1). The difference in medication use in MC compared to indemnity
plans was greater for newer medications. However, for both MC and
indemnity plans a substantial fraction of patients with these three chronic
conditions used no condition-specific medications.
Medications for Diabetes Mellitus
For patients with DM, those enrolled in MC plans were more likely to receive
medications for their DM. Although this pattern applied to both older and
newer medications, the magnitude of the differences was greater for newer
medications. Second generation sulfonylureas were more likely to be used by
patients in MC (42 percent versus 37 percent, po 0.001), but not by the small
numbers still using first-generation sulfonylureas (1.3 percent versus 1.5
percent, p5NS). The differential between MC and indemnity was even more
substantial for newer agents. Metformin was a third more likely to be used
by MC patients (26 percent) compared to indemnity patients (18 percent,
p o 0.001). Similarly, troglitazone was 38 percent more likely in MC (8.8
percent) than in indemnity (6.4 percent, p o 0.001). While insulin use was
slightly higher in MC patients (23 percent) compared to indemnity (21
percent, p5 0.02), this difference disappeared in multivariate analysis that
adjusted for patient case mix ( p5NS). Aside from the case of insulin, the
other findings of higher medication use remained statistically significant in
multivariate analysis. As with the unadjusted analysis, the largest differential
was noted for metformin (adjusted odds ratio 1.29, 95 percent CI 1.21–1.39).
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Medications for Congestive Heart Failure
For CHF patients, too, those in MC plans were more likely to receive a range
of medications, including both older and, especially, newer medications.
Patients enrolled in MC plans showed greater use of loop diuretics (45 percent)
compared to patients in indemnity plans (41 percent, po 0.001). The use of
ACE inhibitors or ARBs was more likely in MC (49 percent) compared to
indemnity (40 percent, p o 0.001). The use of beta-blockers (including
carvedilol) in MC (25 percent) was greater than in indemnity (16 percent) by a
similar magnitude ( p5 0.001). However, use of digoxin, an older medication,
was the same in MC patients (32 percent) and indemnity patients (32 percent,
p5NS). In multivariate analysis to adjust for patient case mix, MC was
independently associated with higher rates of medication use for these
medications at po 0.001, with the exception of loop diuretics ( p5 0.003) and
digoxin (NS). As with the unadjusted analysis, the largest differential was
noted for beta-blockers (adjusted odds ratio 1.38, 95 percent CI 1.21–1.57).
Given the prominence of ACE inhibitors in clinical guidelines, their use was
relatively low in both MC and indemnity patients with CHF.
Medications for Asthma
For asthma patients, as well, those covered by MC plans were more likely to
use medications. As with CHF and DM, increased medication use in MC was
most dramatic for newer drugs, but applied to some older drugs, as well. The
chance of an asthma patient receiving inhaled corticosteroids was greater in
MC (34 percent) compared to indemnity (30 percent, p o 0.001). Similarly,
systemic corticosteroids were more likely in MC (18 percent) than in
indemnity (16 percent, p o 0.02). As a mainstay of treatment, short-acting
beta-agonists were more likely in MC (42 percent) compared to indemnity (33
percent, p o 0.001). Among newer medications, long-acting beta-agonists
were used more frequently by MC patients (9.9 percent) than by indemnity
patients (8.6 percent, p5 0.05). The newest class of medications, leukotriene
modifiers, was 32 percent more common in MC (5.4 percent) compared to
indemnity (4.1 percent, p5 0.01). No differences were found for cromolyn
sodium and its relatives (4.8 percent in MC versus 4.5 percent in indemnity,
p5NS) or for methylxanthines (9.1 percent in MC versus 9.0 percent in
indemnity, p5NS). After multivariate analysis to adjust for potential case-mix
differences, these findings persisted with the largest differences between MC
and indemnity patients noted for leukotriene modifiers (AOR 1.33, 95 percent
CI 1.02–1.72). Given the first-line status that clinical guidelines accord to
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inhaled steroids and inhaled short-acting beta-agonists, their overall use was
relatively low in both MC and indemnity patients.
Analysis of Drug Groupings and by Patient Age
Table 1 shows that for almost all medications for all three diagnoses, patients
with MC coverage were consistently more likely to use the drugs than those with
indemnity insurance. To determine whether those differences are explained in
part by the way the data were analyzed, we grouped similar medications that
could substitute for one another and also analyzed results separately for patients
younger than age 65 and those aged 65 and older. Table 2 shows the results for
the grouped medications. In every case, the probability that MC patients would
use the drugs was higher than that for indemnity patients, and the odds ratios
(adjusted for age, gender, and severity) remained statistically significant.
We also analyzed the patterns of medication use for our three clinical
conditions separately for patients who were younger than 65 years and
65 years or older. For each age group, patients with managed care plans were
more likely to have received chronic disease medications (Table 3). In general,
Table 2: Percent of People with Three Chronic Illnesses Using Particular
Groups of Medications, by Managed Care and Indemnity Insurance, 1997
Comparison
Managed
Care % Indemnity %
Unadjusted
Odds Ratio
(95% CI)
Adjusted
Odds Ratio
(95% CI)
Diabetes
1st or 2d sulfonylureas 42.7 38.2 1.20 (1.14–1.26) 1.22 (1.15–1.29)
All noninsulin hypoglycemicsn 63.0 56.4 1.31(1.25–1.38) 1.35 (1.28–1.44)
(Number) (16,004) (10,440)
CHF
ACE/ARB 48.8 39.5 1.45 (1.33–1.60) 1.18 (1.06–1.31)
Carvedilol or beta-blockers 24.6 16.2 1.68 (1.50–1.88) 1.41(1.24–1.60)
(Number) (2,875) (5,103)
Asthma
Asthma ‘‘controllers’’n 39.2 33.2 1.29 (1.17–1.44) 1.40 (1.24–1.57)
(Number) (7,869) (1,981)
nAll noninsulin hypoglycemics: Sulfonalyureas 1st and 2d, Metformin, Rezulin, and ACE/ARB.
Asthma ‘‘controllers’’ are claims for inhaled steroids, cromolyn, leukoriene, and long-acting beta-
agonists.
Adjusted models are the same as in the first analyses presented in Table 1.
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Table 3: The Percent of People with Three Chronic Illnesses Using
Prescription Medications, by Managed Care and Indemnity Health Insurance
and by Age, 1997
Younger Than Age 65 Aged 65 and Older
Managed
Care Indemnity
Managed
Care Indemnity
Diabetes Mellitus
(Number of members) (11,015) (3,249) (4,989) (7,191)
Sulfonylureas 1stw 0.9 0.6 2.4 2.0
Sulfonylureas 2dw 41.4 31.1nnn 42.7 39.6nnn
Metformin 29.1 18.8nnn 19.8 17.6nn
Troglitizone 9.7 7.0nnn 6.9 6.2
Insulin 25.3 21.1nnn 16.5 21.2nnn
Any DM medication 74.6 58.1nnn 66.8 66.3
Congestive Heart Failure
(Number of members) (1,041) (455) (1,834) (4,648)
Loop diuretics 42.8 31.2nnn 46.2 41.9nn
ACE inhibitors 52.6 37.8nnn 42.3 37.5nnn
ARBs 6.1 3.3n 3.1 3.2
Beta-blockers§ 25.5 16.7nnn 21.8 15.5nnn
Carvedilol 3.9 1.5n 1.2 1.1
Digoxin 31.1 24.8n 33.1 32.9
Any CHF medication 72.0 52.1nnn 63.1 56.4nnn
Asthma
(Number of members) (7,401) (1,344) (468) (637)
Inhaled corticosteroids 34.4 29.0nnn 35.3 31.6
Systemic corticosteroids 17.8 14.9nn 20.5 17.1
Short-acting beta-agonists 42.6 33.9nnn 34.0 31.1
Long-acting beta-agonists 10.0 7.9n 10.3 10.4
Leukotriene modifiers 5.5 3.9n 4.5 4.6
Cromolyn 5.0 4.8 2.8 4.1
Methylxanthines 9.0 8.0 12.4 11.5
Any asthma
medication
56.9 45.5nnn 53.9 48.2
nStatistically significant between managed care and indemnity at po 0.05.
nnStatistically significant between managed care and indemnity at po 0.01.
nnnStatistically significant between managed care and indemnity at po 0.001.
wSulfonylureas 1st refers to first-generation medications in this class, while Sulfonylureas 2d refers
to second-generation medications in this class.
§Excluding carvedilol.
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the magnitude of the managed care versus indemnity differences was smaller
for patients 65 years or older. This pattern, in addition to the relatively smaller
sample sizes for older patients with asthma meant that fewer managed care
versus indemnity differences were statistically significant for older patients.
DISCUSSION
Contrary to public perception, the use of medications for chronic diseases was
consistently more likely in patients covered by MC plans compared to those
covered by indemnity plans. Although this generalization applied to the vast
majority of medications that were examined, it was more pronounced for
newer medications. For example, MC patients with asthma were 32 percent
more likely to use leukotriene modifiers than indemnity patients and
metformin in DM was 44 percent more common in MC compared to
indemnity insurance. These patterns were consistent across DM, CHF, and
asthma patients. The few exceptions included insulin, first generation
sulfonylureas, digoxin, cromolyn, and methylxanthines, all of which are
older medications whose use has been partly supplanted by newer therapies.
Our multivariate analysis generally reduced the magnitude of the observed
MC versus indemnity differences.
Our findings are consistent with past studies comparing medication use
in MC and indemnity plans. In Miller and Luft’s three reviews (1994, 1997,
2002), studies concerned with medication use or chronic disease management
presented a mixed picture, but with relatively few studies showing worse
treatment or outcomes in MC patients. Specific individual studies suggest that
use of chronic disease medications was either equivalent (Coffey et al. 1995) or
more likely (McCormick et al. 1999; Glied 1997) in patients with MC
coverage. Our results also are consistent with speculation that practice
differences in MC may be related to characteristics of coverage, especially
comparative cost-sharing provisions, which lower the barriers to utilization for
MC patients compared to indemnity patients. Our finding of markedly
increased probability of using newer therapies in MC appears to be unique.
Medication Use as a Potential Quality Indicator
The relationship between patterns of medication use and quality of care is
complex. While this study lacks the detailed clinical data that would allow
definitive assessment of this relationship, some tentative conclusions about
quality may be possible. In some cases, the medications we studied are
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recommended therapy and their increased use in MC is a likely associated
with higher quality. For example, the use of ACE inhibitors in congestive heart
failure is strongly recommended as first-line pharmacotherapy (Agency for
Health Care Policy and Research 1994). For some other medications,
increased use in MC could suggest higher quality, but only indirectly. For
example, the finding of greater inhaled steroid use among MC patients may
indicate better quality, with the caveat that the DxCG methodology may not
adequately control for severity between MC and indemnity patients with
asthma. In contrast, the greater use of newly released medications in MC may
not necessarily indicate higher quality. More rapid adoption of new
medications may offer patients the latest technology, but may also mean
abandoning well-established medications in favor of less fully proven
medications.
For CHF, clinical guidelines in existence before 1997 (Agency for
Health Care Policy and Research 1994; Committee on the Evaluation and
Management of Heart Failure 1995) suggest ACE inhibitors as first-line
medications, with the addition of diuretics and then digoxin for patients with
continued symptoms. More recent guidelines (e.g., Hunt et al. 2001) remain
consistent with this approach. These recommendations are based on a survival
benefit for ACE inhibitors not present for diuretics and digoxin alone. Beta-
blockers recently have been recommended as an additional first-line agent,
again based on a survival benefit (Lee and Spencer 2001; Gomberg-Maitland,
Baran, and Fuster 2001). Our findings indicate that use of these recommended
medications is lower for indemnity patients. Use of digoxin, now recom-
mended to play a subsidiary role in treatment (Haji and Movahed 2000; Hunt
et al. 2001), is similar among MC and indemnity patients.
A direct assessment of the quality of DM care from drug prescribing
patterns is not possible with our data. Because adequate blood sugar control
infrequently results from diet alone and not consistently from sulfonylureas
alone (Luna and Feinglos 2001), MC patients’ greater probability of using
medications, especially metformin and troglitazone, may increase the
likelihood of adequate blood sugar control than treatment regimens without
these medications. However, the serious adverse effects of troglitazone and its
subsequent exit from the market (Gale 2001) demonstrate that the newest
medications, with less well-characterized risks and benefits, may also produce
adverse clinical outcomes.
For asthma, current treatment guidelines recommend the use of inhaled
steroids for patients with more than mild asthma (National Heart, Lung and
Blood Institute 1997; Georgitis 1999). These inhalers are often combined with
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the use of control agents such as inhaled beta-agonists. While other agents may
be useful in treatment, the greater use of inhaled steroids among MC patients
may represent better quality of care. In contrast, we found no significant
differences between MC and indemnity patients for methylxanthines, a class
that may be less optimal for the treatment of adult asthma.
Potential Explanations
Our findings are surprising because it appears that not only are MC patients
more likely to use medications than indemnity patients, but also they are more
likely to use the newest, least established, most expensive medications. If MC
plans exercised control over medication use, as many believe, one would
expect them to be slower to adopt relatively unproven, new medications,
especially because they are more expensive. Because this appears not to be the
case, the question is what accounts for our results. Potential explanations
include the following:
1. Higher out-of-pocket costs for indemnity patients may inhibit both
drug-seeking behavior during physician visits and the filling and
refilling of prescriptions.
2. Managed care patients also face lower financial barriers to seeking
physician services and may, therefore, have more opportunities to
obtain prescription medications than patients with indemnity cover-
age.
3. Rather than placing barriers to physician prescribing, these MC plans
may have used formal or informal disease management activities to
encourage use of medications found in published guidelines in the
hope of avoiding higher downstream costs resulting from untreated
illness.
4. Although physicians are paid fee-for-service in both plans and, thus,
have no financial incentive to alter treatment, they may treat
indemnity and managed care patients differently.
Without further analysis, it is difficult to gauge the extent to which each
of these factors contributed to the differences we observed. The benefit
structure of managed care and disease management programs may translate
into differences in medication use through several mechanisms, including a
higher probability of physician visits, a greater willingness of physicians to
prescribe indicated medications, and a greater willingness of patients to fill the
prescriptions they receive. To the extent that they result in higher costs for MC
plans, it follows that to offer more generous coverage for medications,
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offsetting savings must accrue from other sources. These savings may come
from lower rates of hospitalization, shorter lengths of stay, and lower rates of
emergency room visits.
The relationship between insurance type and the use of chronic disease
medications is similar for patients younger than age 65 years and aged 65 and
older (roughly equivalent to patients eligible for Medicare). However, the
increased use of medications associated with managed care plans was of
greater magnitude and more likely to be statistically significant in patients
younger than age 65 years. The less prominent differences for those 65 years
or older may reflect the smaller deductibles for Medicare indemnity patients.
Limitations
Several limitations with our analysis need to be acknowledged. Our results
may not be fully generalizable because they were derived from a single health
care market in 1997. Other geographic markets could potentially have MC
plans that operate differently than the ones we have examined. Given the
rapid flux in health care systems, our findings from 1997 may not reflect
current MC practices. We have used medical claims data to identify
individuals with DM, CHF, and asthma, rather than objective diagnostic
information. Additional clinical information would have helped to verify the
claims-based diagnoses and to provide additional severity information for
case-mix adjustment. For several of the medications we investigated, the
appropriateness of medication use may depend on disease severity.
Our outcomes were based simply on whether or not one or more
prescriptions for specific drugs were filled; we did not consider such issues as
medication dose, patient adherence, or continuity of treatment. While
unmeasured case-mix differences could affect our results, past evidence that
MC patients tend to be healthier than indemnity patients (Hellinger 1998)
makes it less likely that such differences would result in greater MC
medication use. On the other hand, there may be limited instances in which
sicker patients have contraindications that make the use of some medications
less likely.
Similarly, we were unable to determine if some patients had alternative
medication payment sources so that their medication use went unaccounted
for. This may well be of greater importance for indemnity plan patients
because services used before the deductibles have been met may not be
included in the claims data. While this is a potentially serious problem for all
claims-based research, we believe it does not affect the results reported here.
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First, only a very small percentage of patients in each diagnosis group used no
services in 1997 (the range was from 1.6 percent to 4.2 percent). In other
words, almost everyone met the deductible. Second, the outcome reported in
the paper is the proportion of eligibles that used prescription medications
during the year in question, not the amount of their use.
Implications
The perception that MC plans withhold expensive services from its members
does not appear to be supported by our research. While there may be areas
of clinical practice where this phenomenon does operate, it appears not to
have been the case with chronic disease medications in this market provide
an empirical basis for poor performance as the basis for a ‘‘backlash’’ against
MC. Since 1997, an increased proportion of Americans are now enrolled in
decentralized Preferred Provider Organizations (PPOs) in part due to this
backlash. The findings cannot necessarily be generalized to newer MC
arrangements, but should prompt additional assessment of care for persons
with chronic illnesses in organizational arrangements that provide more
flexibility for consumers.
Our study also suggests the need for studies in other markets, as well as
research to more fully define the mechanisms that work to create the observed
MC versus indemnity differences in medication use. Although we have
speculated about possible mechanisms, other studies that seek to isolate the
explanation for our findings will have important policy implications.
NOTES
1. Copayments are a fixed amount (say, $10) each time a service (e.g., a physician
office visit) is used. Coinsurance, in contrast, is a percentage (say, 20 percent) of the
approved payment for each service. Coinsurance, especially when patients must
also pay a deductible before they are eligible for services to be covered, usually
results in substantially higher out-of-pocket payments than copayments.
2. The following codes were used to define the three conditions. Diabetes mellitus was
defined by ICD-9 codes 250, 357.2, 362.0, or 648.0. Congestive heart failure was
defined by ICD-9 codes 425.4, 428, 398.91, 402.11, 402.91, 404.01, 404.11, 404.02,
404.13, 404.93, or 996.83. Asthma was defined as patients with ICD-9 codes of
493.0, 493.1, or 493.9, but lacking any other ICD-9 code indicating chronic
obstructive pulmonary disease, emphysema, or chronic bronchitis (491, 492, 493.2,
494, 496, 506.4 or 506.9).
3. The following parameters were included in the regression models. The models for
DM medications made use of the following HCC groupings as covariates: Coronary
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Artery Disease (low, moderate, and high cost, separately; HCCs 50, 51, and 52),
CHF (HCC048), Diabetes Mellitus (low, moderate, and high cost, separately; HCCs
13,14, and 15), Depression (HCC 33), Renal Failure (HCCs 76,77, and 78 together),
and Skin Ulcers (HCC 91). The CHF medication regression models used: Heart
Disease (HCC 54), Coronary Artery Disease (low, moderate, and high cost,
separately; HCCs 50, 51, and 52), CHF (HCC 48), Diabetes Mellitus (low,
moderate, and high cost, separately; HCCs 13,14, and 15), Cardiac Arrest (HCC
46), Arrhythmia (HCCs 49, 56, separately), Valvular Disease (HCC 53), Other
Heart Condition (HCC 55), Depression (HCC 33). The asthma medication
regression models employed Asthma (HCC 70), COPD (HCC 64), Pneumonia
(HCC 65, 66, and 67 together), Pulmonary Fibrosis (HCC 68), Other Lung Disease
(HCC 71), and Depression (HCC 33).
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